Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
6.07
-2.46 (-28.84%)
Jun 1, 2026, 1:31 PM EDT - Market open
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $145.95K in the quarter ending March 31, 2026, with 190.30% growth. This brings the company's revenue in the last twelve months to $718.17K, down -79.47% year-over-year. In the year 2025, Co-Diagnostics had annual revenue of $622.49K, down -84.10%.
Revenue (ttm)
$718.17K
Revenue Growth
-79.47%
P/S Ratio
43.44
Revenue / Employee
$6,245
Employees
115
Market Cap
22.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 622.49K | -3.29M | -84.10% |
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.91% |
| Dec 31, 2019 | 214.97K | 175.06K | 438.63% |
| Dec 31, 2018 | 39.91K | 32.25K | 420.90% |
| Dec 31, 2017 | 7.66K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 10.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| Nortech Systems | 121.79M |
| TELA Bio | 80.81M |
| Myomo | 41.21M |
| Cytosorbents | 37.20M |
| Lifeward | 20.92M |
| NeuroOne Medical Technologies | 12.72M |
| Pulsenmore | 12.55M |
CODX News
- 3 days ago - Co-Diagnostics files to sell 4.94M shares of common stock for holders - TheFly
- 4 days ago - Co-Diagnostics Registration statement: Registration filing - Filings
- 5 days ago - Co-Diagnostics trading halted, volatility trading pause - TheFly
- 5 days ago - Co-Diagnostics trading resumes - TheFly
- 6 days ago - Co-Diagnostics and CoSara Diagnostics advance with ebola PCR development - TheFly
- 6 days ago - Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara - PRNewsWire
- 12 days ago - Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 13 days ago - Co-Diagnostics develops ebola assay strategy after recent global outbreak alert - TheFly